Lonza Participates in the United Nations Global Compact

March 24,2009 Basel, Switzerland

Lonza announces its participation in the United Nations Global Compact. Lonza wholeheartedly supports the ten principles of the Global Compact with respect to human rights, labor, environment and anti-corruption and is committed to the ongoing integration of the Global Compact principles into its strategy, culture and day-to-day operations.

This participation is a natural fit to Lonza’s longtime commitment to ethical, social and environmental responsibility, described in the Lonza Code of Conduct. The Lonza Code of Conduct is a key element of Lonza’s relations with employees and third parties and delineates the professional standards the company aspires in all its activities and expects from its employees. The Lonza Code of Conduct can be found here.

Stefan Borgas, Chief Executive Officer of Lonza, comments: “We are delighted to participate in the United Nations Global Compact, underlining this way our responsibility towards our customers, our employees, our shareholders, our communities and towards society in general. For Lonza, corporate social responsibility is not just a technical term but an active commitment that is essential to all our employees. It is our commitment to act in accordance with all legal environmental and social requirements while pursuing our economic goals.”


About Lonza

Lonza is one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries. Its products and services span its customers’ needs from research to final product manufacture. Lonza is the global leader in the production and support of active pharmaceutical ingredients both chemically as well as biotechnologically. Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. Lonza has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts which play an important role in the development of novel medicines and healthcare products. Lonza is a leader in cell-based research, endotoxin detection and cell therapy manufacturing. Lonza is also a leading provider of value chemical and biotech ingredients to the nutrition, hygiene, preservation, agro and personal care markets.

Lonza is headquartered in Basel, Switzerland and is listed on the SIX Swiss Exchange. In 2008, Lonza had sales of CHF 2.937 billion. Further information can be found at www.lonza.com.


For further Information:

Head of Corporate Communications
Michael Frizberg
Tel +41 61 316 8624
Fax +41 61 316 9624

Media Relations
Dominik Werner
Tel +41 61 316 8798
Fax +41 61 316 9798

Investor Relations
Alexandre Pasini
Tel +41 61 316 8835
Fax +41 61 316 9835

Browse All News